Psoriasis Therapy
Pharmacokinetics of efalizumab in psoriasis patients described
Published in Medical Letter on the CDC and FDA, June 5th, 2005
According to a study from the United States, "The population pharmacokinetics of efalizumab was characterized in patients with moderate to severe plaque psoriasis. The study included 1,088 subjects who received 1 or 2 mg/kg/wk subcutaneous efalizumab for 12 weeks from a phase 1 (64 subjects) and 3 phase III studies with day 42 and/or day 84 trough levels (1024 patients). Due to the limitation of the data, a one-compartment model...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Chickenpox Vaccine
Failure to get catch-up vaccinations causes varicella outbreak - Ebola Vaccine
CD8-mediated protection against Ebola infection is perforin dependent - Environmental Health
Organophosphorus pesticide exposure assessed by biomonitoring - Environmental Health
Urinary levels of bisphenol A and 4-nonylphenol in humans measured - Heart Disease Risk Factors
Trends in heart disease risk factors according to BMI reported - Addiction Medicine
Admissions for drug treatment up for older adults - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
